Altacor’s current product range comprises around four product categories,
Dry Eye Syndrome
Dry Eye syndrome (DES) is caused either by decreased or abnormal tear production or increased tear evaporation as a result of abnormal tear composition. DES caused by rapid evaporation is termed evaporative dry eye. In this case, the tear gland produces sufficient tears, but the rate of evaporation is too rapid. Where there is a loss of water from the tears and they become too "salty" or hypertonic. Consequently, the entire conjunctiva and cornea cannot be kept covered with a complete layer of tears during strenuous activities or in certain environments. If DES is left untreated or becomes severe, it can produce complications that can cause ocular inflammation or infection resulting in impaired vision or in rare cases the loss of vision.
The prevalence of DES increases with age, and approximately 10% of adults over the age of 40 years suffer from Dry Eye.
The objective for the treatment of DES is improvement in tear production and quality.
Dry Eye Prescription Products
Clinitas Gel Rx
Clinitas Gel is a liquid gel for the treatment of Dry Eye. It contains carbomer 980, a synthetic polymer and is formulated to produce a transparent, lubricating film covering the cornea and conjunctiva.
Clinitas & Clinitas Multi Rx
Clinitas Rx is a preservative-free eye drop that contains sodium hyaluronate 0.4%, an ophthalmic lubricant, for the relief of DES. This popular product is now available in both unit dose and multi dose formats.
Dry Eye Retail Products
This range also comprises three products which together cover mild, moderate and severe Dry Eye and are recommended by pharmacists and opticians.
This is the sister product to Clinitas Gel and is used in an identical manner when recommended by optical professionals and sold over the counter.
Clinitas Soothe and Clinitas Soothe Multi
Clinitas Soothe and Clinitas Soothe Multi are retail versions of Clinitas Rx. It is stocked in a number of leading pharmacies (e.g. Boots) and optical chains (e.g. Vision Express, Specsavers) and is designed to be used by patients who have moderate Dry Eye.
Blepharitis is an irritation of the eyelid margin which may have inflammatory elements and is allied to Dry Eye. It is associated with meibomian gland dysfunction and treatment is focussed towards restoring meibomian functionality. Altacor’s products, when used together, are an effective means of achieving this.
BlephaMask is a reusable eye mask containing a temperature tester to ensure optimum working temperature for safety and efficacy. Applied to the closed eye for 10 minutes, BlephaMask liquefies and loosens meibomian secretions.
BlephaCura is used to remove meibomian secretions loosened by BlephaMask and as a daily eyelid cleaner to promote eyelid hygiene and health. BlephaCura encourages and promotes the natural healing process in response to inflammation and irritation of the eyelids.
Age-related Macular Degeneration (AMD) and AREDS
AMD is the leading cause of blindness in patients over the age of 50 years in the industrialised world. There are two types of macular degeneration, the non-exudative (dry) and exudative (wet; neovascular) forms. Although dry AMD is more common, wet AMD accounts for more than 80% of the cases with severe loss of vision. In wet AMD, abnormal blood vessels grow under and into the retina in a process called choroidal neovascularisation (CNV). These new blood vessels leak fluid into and under the retina accompanied by the deposition of fibrous tissue which results in visual deterioration over days to months.
AREDS (Age Related Eye Disease Study) is a large clinical investigation sponsored by the US National Eye Institute to investigate the impact of vitamins (vitamins C and E) and minerals (copper and zinc) on the progression of AMD. The original AREDS study (AREDS-1) was completed in 2001 and showed that high dose antioxidant vitamins and minerals (including vitamins C and E, beta-carotene, zinc and copper) reduced the risk of patients progressing to advanced AMD by 25% and the risk of patients experiencing moderate vision loss by 19%.
A second study (AREDS-2) was conducted to determine if the addition of the xanthophylls (lutein and zeaxanthin) and omega-3 would further reduce the progression to advanced AMD compared to the original AREDS-1 supplement formulation. Previous clinical studies have been carried out which suggest these nutrients protect vision. In the AREDS-2 study the addition of lutein and zeaxanthin to the AREDs-1 formula showed a 10% decrease in the risk of progression to advanced AMD. The overall outcome of the study is that the addition of lutein and zeaxanthin to the AREDS-1 formula improves patient outcome and that these two xanthophylls are important to macular health.
Altacor’s Nutritional ARED2s Supplement
EyeBar – to maintain healthy vision
EyeBar is an orange flavoured chocolate micronutrient mixture based on the latest AREDS clinical research. The recent results from the AREDS 2 study (as above) showed that EyeBar’s formula contains all the effective components. Traditional tablet and capsule products sometimes have problems with palatability and ingestion, being large and difficult to swallow. In comparison, EyeBar is taste masked and easy and pleasant to eat, improving compliance and thereby effectiveness. Despite there being a large number of patients with dry AMD there are no registered therapeutic approaches beyond AREDS formulations.
BioLon - 1% sodium hyaluronate viscoelastic
Altacor is pleased to announce that from 1st April 2016 it is assuming the exclusive responsibility from Kestrel Ophthalmics for the marketing of BioLon®, a viscoelastic for use in cataract and other ophthalmic surgery.
BioLon® contains highly engineered, ultrapure hyaluronic acid (1%) with optimised viscosity in an easy to use 1ml syringe which is designed to be bubble free. BioLon® can be reliably used wherever anterior chamber depth maintenance is important. It protects endothelial cells and is easy to remove after the procedure is complete due to its cohesive nature.
BioLon® is the first product in Altacor’s new ophthalmic surgical portfolio which will be expanded with further complimentary products.
BioLon® will continue to be available direct from Alloga or AAH. Please contact your Altacor Representative for further information or call Altacor on 01223 421411 and we will be pleased to assist you.